Top Buy Stocks
Sign In
Invest in BLRX
$4.88
-0.0400 (-0.81%)
At Close: Jul 10, 2025
3 Stocks Getting Rare Double Upgrades From Analysts
02:30pm, Friday, 06'th Jun 2025
Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts' expectations.
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
01:58pm, Friday, 30'th May 2025
BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 Am
BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript
12:55pm, Tuesday, 27'th May 2025
BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2025 Earnings Conference Call May 27, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Philip Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chie
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 27'th May 2025
- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Pha
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
07:00am, Tuesday, 20'th May 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 20, 2025 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript
10:52am, Monday, 31'st Mar 2025
BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chie
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
07:00am, Monday, 31'st Mar 2025
- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. f
BioLineRx to Report 2024 Annual Results on March 31, 2025
07:00am, Monday, 24'th Mar 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Issues Letter to Shareholders
07:00am, Tuesday, 21'st Jan 2025
- Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel , Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical co
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
07:00am, Friday, 17'th Jan 2025
TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases,
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
02:01pm, Monday, 06'th Jan 2025
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday.
BioLineRx Announces $10 Million Registered Direct Offering
08:57am, Monday, 06'th Jan 2025
TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapi
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
10:58am, Monday, 25'th Nov 2024
BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Mali Zeevi - CFO C
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
06:30am, Thursday, 21'st Nov 2024
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
07:19am, Wednesday, 20'th Nov 2024
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.
